Global Stem Cell Reconstructive Market Size, Share, Forecast Report, 2020-2027

Stem cell reconstructive surgery involves the treatment of injured or damaged part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. The major factors contributing to the market growth are increasing number of geriatric population, rising number of patients suffering from chronic diseases, and continuous development in the technology. Furthermore, the increasing need for the alternative treatments, government support for the development of the new products, and increasing healthcare expenditure have fuelled the growth of the market. However, higher cost for treatment and strict regulatory rules by the government for approval of the therapy may restraint the growth of the market.

The global stem cell reconstructive market is expected to grow at a CAGR of 22.6% during the forecast period 2017-2023
Segmentation

The global stem cell reconstructive market is segmented into sources, cell types, applications, and end users. On the basis of sources the market is categorized: allogeneic, autologous, syngeneic, and others. Autologous is further segmented into bone marrow, adipose tissue, and blood. On the basis of cell types, the market is segmented into embryonic stem cell and adult stem cell. On the basis of application the market is segmented into cancer, diabetes, traumatic skin defect, severe burn, and others. On the basis of end users, the market is segmented into hospital, research institutes, and others.

Key Players for Global Stem Cell Reconstructive Market

The major key player in the global stem cell reconstructive market: Baxter (US), Cytori Therapeutics Inc. (U.S), Eleveflow (France), Mesoblast Ltd. (Australia), NuVasive Inc. (US), Osiris Therapeutics, Inc. (US), Micronit Microfluidics (Netherlands), TAKARA BIO INC.(Japan), Tigenix (Belgium), Cynata (Australia), Celyad (Belgium), Capricor Therapeutics (Canada), Astellas Pharma US, Inc. (US), Pfizer Inc. (US), StemCells Inc (US), STEMCELL Technologies Inc. (US), Caladrius (US).